- Five-Year Business Highlights
- Quarter Business Highlights
Principal Financial Data
| Fiscal year (millions of yen) |
ending March 2024/Q1 （IFRS） | ending March 2024/Q1~2 （IFRS） | ending March 2024/Q1~3 （IFRS） | ending March 2024/Q1~4 （IFRS） | ending March 2025/Q1 （IFRS） | ending March 2025/Q1~2 （IFRS） | ending March 2025/Q1~3 （IFRS） | ending March 2025/Q1~4 （IFRS） | ending March 2026/Year Ended (forecast) （IFRS） |
|---|---|---|---|---|---|---|---|---|---|
| Sales revenue | 37,012 | 73,314 | 112,728 | 148,255 | 39,131 | 79,332 | 121,320 | 160,232 | 173,000 |
| Pharmaceuticals | 30,870 | 60,988 | 94,606 | 125,105 | 33,738 | 68,496 | 104,560 | 138,654 | 150,000 |
| Functional food | 6,142 | 12,325 | 18,121 | 23,150 | 5,393 | 10,836 | 16,759 | 21,577 | 23,000 |
| Operating income | 11,163 | 20,878 | 30,450 | 33,295 | 11,078 | 17,867 | 32,752 | 35,450 | 30,000 |
| Profit attributable to owners of the parent | 8,749 | 16,176 | 24,002 | 25,851 | 10,264 | 16,373 | 28,552 | 32,558 | 24,000 |
| Depreciation and amortization | - | 2,462 | - | 5,023 | - | 2,980 | - | 6,015 | 7,950 |
| Capital investment | - | 3,358 | - | 6,921 | - | 2,189 | - | 5,055 | 5,750 |
| R&D expenses | 5,911 | 12,517 | 19,500 | 31,676 | 7,497 | 16,732 | 23,547 | 34,341 | 39,500 |
| Total assets | 237,408 | 249,499 | 247,830 | 263,404 | 265,828 | 268,542 | 284,459 | 283,637 | |
| Total equity | 202,799 | 211,774 | 215,316 | 220,534 | 227,462 | 235,252 | 247,782 | 247,340 |
Sales revenue
Operating income
Net income attributable to owners of the parent
R&D expenses
Cash Flows
| Fiscal year (millions of yen) |
ending March 2024/Q1 （IFRS） | ending March 2024/Q1~2 （IFRS） | ending March 2024/Q1~3 （IFRS） | ending March 2024/Q1~4 （IFRS） | ending March 2025/Q1 （IFRS） | ending March 2025/Q1~2 （IFRS） | ending March 2025/Q1~3 （IFRS） | ending March 2025/Q1~4 （IFRS） |
|---|---|---|---|---|---|---|---|---|
| Cash flow from operating activities | 526 | 7,938 | 8,126 | 16,289 | 7,004 | 17,732 | 17,125 | 36,126 |
| Cash flow from investing activities | △2,060 | △1,693 | △2,654 | △9,921 | △6,788 | △13,340 | △11,413 | △28,877 |
| Cash flow from financing activities | △4,047 | △4,685 | △9,046 | △9,719 | △4,328 | △4,996 | △9,248 | △9,902 |
Business Forecast and Outlook
Consolidated business forecast for the fiscal year ending March 2026 (April 1, 2025–March 31, 2026)
| Sales revenue | Operating income | Profit before tax | Profit attributable to owners of the parent | Basic earnings per share | |
|---|---|---|---|---|---|
| Consolidated business forecast (millions of yen) | 173,000 | 30,000 | 30,600 | 24,000 | 356.20 |
| Year on year rate | 8.0 | △15.4 | △15.3 | △26.3 |
(Percentage figures represent year-on-year rate of changes.)